The Phase 3 study (NCT04889430) investigating iptacopan for adult patients with atypical hemolytic uremic syndrome (aHUS) completed its primary data collection on 2026-04-11. This trial evaluated the efficacy and safety of iptacopan in patients naive to complement inhibitor therapy.
Background
Iptacopan is being investigated for the treatment of atypical hemolytic uremic syndrome (aHUS). aHUS is a rare, life-threatening genetic disease characterized by uncontrolled activation of the complement system, leading to hemolytic anemia, thrombocytopenia, and acute kidney injury. This particular study focused on adult patients who had not previously received complement inhibitor therapy.
Trial design
The Phase 3 study (NCT04889430) was designed to assess the efficacy and safety of iptacopan in adult patients with atypical hemolytic uremic syndrome. The trial enrolled 34 participants who were naive to complement inhibitor therapy. The study's objective was to determine whether iptacopan is efficacious and safe for this patient population.
What this means
The completion of this Phase 3 trial represents a significant step in the clinical development of iptacopan for atypical hemolytic uremic syndrome. Data from this study, once available, will provide crucial insights into the potential of iptacopan as a treatment option for adult patients with aHUS who are naive to complement inhibitor therapy.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The completion status for study NCT04889430, titled "Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy," was updated on 2026-04-11 on clinicaltrials.gov.